Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
A total of 120 patients with unresectable, locally advanced esophageal squamous cell carcinoma patients will be enrolled in this study and randomly divided into two groups. Arm A: After 2 cycles of induction adebrelimab plus chemotherapy, patients will be treated with concurrent chemoradiotherapy (50.4Gy/1.8Gy/28f), and adebrelimab will maintain to PD or for a maximum of 15 cycles. Arm B: Patients will be treated with concurrent chemoradiotherapy (50.4Gy/1.8Gy/28f) and adebrelimab will maintain to PD or for a maximum of 17 cycles. This study will compare the efficacy of immunotherapy in the induction and maintenance phases of radiotherapy, optimize more precise treatment plans, and potentially further increase the survival of ESCC patients.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjent wyraził zgodę na udział w badaniu i będzie współpracował przy wizytach kontrolnych.
- •Wiek od 18 do 75 lat, mężczyźni i kobiety.
- •Rak płaskonabłonkowy przełyku w zaawansowanym stadium miejscowym, który nie kwalifikuje się do operacji.
- •Nieprzyjmowanie wcześniej żadnych innych leków przeciwnowotworowych.
- •Ogólny stan zdrowia pozwalający na leczenie (wg skali ECOG 0 lub 1).
- •Próbka guza do badań (preferowane świeże próbki).
- •Oczekiwana długość życia co najmniej 3 miesiące.
- •Odpowiednia liczba komórek krwi i prawidłowe funkcjonowanie nerek i wątroby.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- July 29, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (7)
Beijing Cancer Hospital
Beijing, China
National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, China
Henan Cancer Hospital
Zhengzhou, China
Liaoning Cancer Hospital
Shenyang, China
Shanxi Cancer Hospital
Taiyuan, China
Sichuan Cancer Hospital
Chengdu, China
Tianjin Medical University Cancer Institute and Hospital
Tianjin, China
Trial contact
Wencheng Zhang, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/31/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.